Bleeding Events After Triple Antithrombotic Therapy Initiation. (HEMOTRI)

Central Hospital, Nancy, France

Status: Unknown

Conditions: Bleeding

Treatments: Other: Triple antithrombotic therapy

Study type: Observational

Funder types: Other

Identifiers

NCT03203980

2017-A01733-50

Details and patient eligibility

About

The optimal antithrombotic therapy for patients requiring anticoagulation after coronary stenting is unknown. Double platelets suppressive agents combined with oral anticoagulation (triple antithrombotic therapy) remains the Gold standard.

Our study aims at studying bleeding events occurring until 6 months after the initiation of triple antithrombotic therapy.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients requiring triple antithrombotic therapy, including double antiplatelets agents and oral anticoagulation

Exclusion criteria

• history of bleeding
• patients already under triple antithrombotic therapy
• patients under vitamin K antagonists